SCHEMBL4814523

SCHEMBL4814523

Cc1snc(SCc2cccc(Cl)c2)c1C1=NCCCN1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.58
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
POLB P06746 1/20 0.40
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
THRB P10828 1/20 0.39
NPC1 O15118 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
DAO P14920 1/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4911933 0.94 L3MBTL1 (0.53) L3MBTL1KMT2AMEN1POLBCDC7
SCHEMBL4071760 0.76 L3MBTL1 (0.63) L3MBTL1KMT2AMEN1LMNATSHR
Hydrochloric Acid SCHEMBL10907120 0.68 L3MBTL1 (0.56) L3MBTL1KMT2AMEN1ALDH1A1HPGD
SCHEMBL5732708 0.68 L3MBTL1 (0.82) L3MBTL1KMT2AMEN1THRBDAO
SCHEMBL9869963 0.66 L3MBTL1 (0.59) L3MBTL1KMT2ALMNATSHR
SCHEMBL4823615 0.63 NISCH (0.57) L3MBTL1KMT2AMEN1TSHR
SCHEMBL4068865 0.63 L3MBTL1 (0.46) L3MBTL1KMT2AMEN1POLBTSHR
SCHEMBL4068101 0.62 NPC1 (0.47) L3MBTL1KMT2AMEN1POLBNPC1
SCHEMBL23901775 0.62 NISCH (0.53) L3MBTL1KMT2AMEN1TSHR
SCHEMBL4159436 0.62 NISCH (0.49) L3MBTL1KMT2AMEN1DAOTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-6699873-B1 EATING DISORDERS MILLENNIUM PHARMACEUTICALS, INC. 2004-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof MC4R, MC5R, MC3R L3MBTL1 326/4885KMT2A 1838/4885MEN1 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.